Andrew R. Clamp, MD, PhD, on High-Risk Ovarian Cancer: Weekly Dose-Dense and Every-3-Week Chemotherapy Plus Bevacizumab

November 26, 2025 By The ASCO Post Staff

Andrew R. Clamp, MD, PhD, of The Christie NHS Foundation Trust, reviews results of the phase III ICON8B trial, which found that in patients with high-risk stage III to IV epithelial ovarian cancer, the use of dose-dense weekly paclitaxel in combination with every-3-week carboplatin and bevacizumab as first-line systemic therapy improved median overall survival compared to standard every-3-week dosing (Abstract 1064O). 

Related Content